Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
700.00    -10.00 (-1.41%)
Bid:
700.00
Ask:
706.00
Spread: 6.00 (0.857%)
Market Cap: £346.93m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Increase in Debt Facilities to Support M&A

18 Sep 2025 15:28

RNS Number : 9282Z
Elixirr International PLC
18 September 2025
 

19 September 2025

ELIXIRR INTERNATIONAL PLC

Increase in Debt Facilities to Support M&A Activity

 

Elixirr International plc ("Elixirr", the "Company" or, together with its subsidiary undertakings, the "Group"), an established, global award-winning challenger consultancy, is pleased to have agreed an increase in the Group's revolving credit facility (the "Facility") with National Westminster Bank Plc from £45 million to £65 million and the option of a US$20.25 million term loan (the "Loan") to support delivery of the Group's organic and inorganic growth strategy, whilst limiting equity dilution.

The key terms of the Facility are:

· £65 million facility with the flexibility to be drawn in multiple currencies, including Pound Sterling and United States Dollar;

· unchanged interest rate margin of 1.95 - 2.60 per cent, dependent on leverage, over SONIA (Sterling Overnight Index Average) or SOFR (Secured Overnight Financing Rate), dependent on currency;

· revolving facility, with flexibility to be drawn and repaid, with the undrawn portion only subject to a commitment fee of 35 per cent of the above margin;

· standard leverage and interest cover covenants; and

· four-year term, with a one-year extension option if mutually agreed.

The key terms of the Loan are:

· US$20.25 million loan to be drawn in United States Dollar;

· available to be drawn within one month of signing with no arrangement fee payable if not drawn;

· interest rate margin equivalent to the Facility; and

· quarterly capital repayments commencing in June 2026, with the Loan fully repaid by June 2027.

 

Stephen Newton, Founder & CEO of Elixirr, commented:

 

"We are pleased to have secured this increase in our debt facilities, which strengthen our ability to pursue M&A as a core part of our growth strategy while maintaining discipline around equity dilution and shareholder value."

 

Enquiries:

For enquiries, please refer to the Company's Investor Contacts page:

https://www.elixirr.com/investors/investor-contacts

Elixirr International plc +44 (0)20 7220 5410  

Stephen Newton, Chief Executive Officer

Graham Busby, Deputy Chief Executive Officer

Nick Willott, Chief Financial Officer and Company Secretary

investor-relations@elixirr.com

 

Cavendish Capital Markets Ltd (Broker) +44 (0)20 7220 0500

Stephen Keys, Callum Davidson, Isaac Hooper (Corporate Finance),

Sunila de Silva (ECM)

 

About Elixirr International plc

Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies. Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr was quoted on the AIM market of the London Stock Exchange in 2020 and listed on the Main Market of the London Stock Exchange in July 2025. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAANPFELSEFA
Date   Source Headline
2nd Jun 20269:49 amRNSNotice of AGM and Dividend Timetable
20th May 20267:00 amRNSIssue of Equity - TRC Contingent Consideration
14th May 20268:38 amRNSHolding(s) in Company
29th Apr 20263:59 pmRNSHolding(s) in Company
29th Apr 202611:18 amRNSPublication of 2025 Annual Report
28th Apr 20265:59 pmRNSResult of Secondary Placing
28th Apr 20264:35 pmRNSProposed Secondary Placing
20th Apr 20267:00 amRNSResults for the year ended 31 December 2025
10th Apr 20267:00 amRNSHolding(s) in Company
27th Mar 20267:00 amRNSNotice of FY 25 Investor Presentation
23rd Mar 20267:00 amRNSGrant of Share Options
19th Mar 202610:09 amRNSDirector/PDMR Shareholding
27th Feb 202610:26 amRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSAcquisition of Kvadrant Consulting A/S
30th Jan 20267:00 amRNSAppointment of Non-Executive Director
22nd Jan 20267:00 amRNSTrading Update and Interim Dividend
9th Jan 20264:37 pmRNSPDMR Shareholding
25th Sep 20258:08 amRNSDirector/PDMR Shareholding
22nd Sep 20257:01 amRNSInterim Results
22nd Sep 20257:00 amRNSAcquisition of TRC Advisory, LLC
18th Sep 20253:28 pmRNSIncrease in Debt Facilities to Support M&A
17th Sep 20257:00 amRNSNotice of H1 25 Investor Presentation
15th Sep 20257:00 amRNSMove from SETSqx to SETS
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSChange of Adviser
1st Jul 20258:00 amRNSReadmission - Elixirr International Plc
1st Jul 20257:00 amRNSAdmission to Main Market
26th Jun 20256:00 pmRNSElixirr International
24th Jun 20253:44 pmRNSPublication of Prospectus
24th Jun 202512:39 pmRNSResult of AGM
10th Jun 20257:00 amRNSGrant of Share Options
30th May 20257:00 amRNSMain Market Update & Capital Markets Day
29th May 20253:58 pmRNSPDMR Dealings and EBT Transfers
29th May 20257:00 amRNSPosting of Annual Report and Accounts
21st May 20257:00 amRNSCapital Markets Day
8th May 202512:21 pmRNSHoldings in Company – Employee Benefit Trust
28th Apr 20257:00 amRNSFinal Results
11th Mar 20257:00 amRNSNotice of FY24 Investor Presentation
18th Feb 20257:00 amRNSTrading Update
22nd Jan 20257:00 amRNSGrant of Restricted Share Awards
17th Jan 20251:40 pmRNSPurchase of Shares by Employee Benefit Trust
16th Jan 20253:05 pmRNSDirector/PDMR Shareholding
13th Jan 20258:06 amRNSBoard Appointment
6th Jan 20257:00 amRNSAppointment of Joint Broker
20th Dec 20244:20 pmRNSDirector/PDMR Shareholding
20th Dec 20247:00 amRNSInterim Dividend
10th Dec 20247:00 amRNSBoard Changes
25th Nov 20247:00 amRNSChange of Adviser
31st Oct 20247:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.